Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
University of Illinois College of Medicine at Peoria
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02958566CT.gov Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Rectal Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oxycodone Hydrochloride, Hydrocodone- (this asset) | University of Illinois College of Medicine at Peoria | Approved | BB · 65 |
| Oxaliplatin | Chongqing University Cancer Hospital | P3 | BB |
| Ertapenem | University of Ulm | P4 | BB |
| Fluorouracilum | Pei-Rong Ding | P3 | BB |
| Propofol | Uppsala University | P4 | BB |
| Sevoflurane | Uppsala University | P4 | BB |
| Capecitabine | Chongqing University Cancer Hospital | P3 | BB |
| Lidocaine | University of Illinois College of Medicine at Peoria | P4 | BB |
| Nepenthe | University of Illinois College of Medicine at Peoria | P4 | BB |
+36 more in the Rectal Neoplasm cohort
Other indications for Oxycodone Hydrochloride, Hydrocodone-
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Pain Syndrome | — | P4 | BB · 69 |
| Vascular Dementia | — | P4 | BB · 68 |
| Diverticulitis Of Colon | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Oxycodone Hydrochloride, Hydrocodone- in Rectal Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/oxycodone-hydrochloride-hydrocodone-rectal-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →